Who Is Eligible for CAR-T Therapy — The Criteria, Stated Plainly

CAR-T therapy is offered to a narrow group. You need a diagnosis in the small set of B-cell blood cancers with an approved CAR-T use, disease that has relapsed or not responded after the specified earlier lines of treatment, and enough organ reserve to survive cell collection, a manufacturing wait and the inflammatory reaction after infusion.

All three gates have to open. A family often clears the first, assumes the rest will follow, and spends months chasing a referral before learning that the second or third gate was shut from the beginning. That is the single most useful thing to understand early, and it is why this page puts the criteria before the explanation.

Gate one is the disease. CAR-T works by recognising one protein on the surface of the cancer cell — CD19 on B-cell leukaemia and lymphoma cells, BCMA on myeloma cells. If your cancer does not carry the protein the cells are built to find, there is nothing for them to attack. That rules out myeloid leukaemias, T-cell lymphomas and every solid tumour outside a clinical trial.

Gate two is the line of treatment. CAR-T is not a first-choice treatment for anything. Approvals are written for relapsed or refractory disease after a defined number of earlier lines, and that number differs by diagnosis and by regulator.

Gate three is fitness. The treatment asks a great deal of the body in a short window, and centres will not accept a patient who is unlikely to get through it. Fitness is assessed as organ function and performance status, not as age.

Said plainly, before anything else: CION Cancer Clinics does not provide CAR-T cell therapy or any other cell therapy. We do not administer it, stock it or manufacture it. This page exists so you can work out whether you are anywhere near the criteria, and so we can point you to an accredited cell-therapy centre if your diagnosis is one where CAR-T is genuinely discussed.

India has a domestically developed CAR-T therapy approved by CDSCO and delivered through a limited network of accredited centres. Approval status is specific to each therapy and changes over time, so confirm the current position directly with an accredited centre rather than relying on a news article.

Exact thresholds are set per therapy and per centre, and guideline bodies including NCCN and ESMO describe the categories rather than a single universal number. Ask the accredited centre for its written criteria instead of assuming that a figure you read online applies to you.

• A diagnosis outside the approved indications — a myeloid leukaemia, a T-cell lymphoma or any solid tumour has no routine CAR-T option. This is permanent, and no referral changes it.
• The target protein is absent — if the cells no longer carry the antigen the therapy is built to recognise, the therapy has nothing to find. This can also happen after a previous antigen-directed treatment.
• Active uncontrolled infection — usually temporary. Treating the infection first can reopen the door.
• Significant organ dysfunction — heart, lung, kidney or liver function below the protocol threshold. Sometimes correctable, often not.
• Frailty or a poor performance status — a body that cannot absorb a severe reaction. Occasionally reversible with nutrition, transfusion support and time.
• Active central nervous system disease or an uncontrolled seizure disorder — excludes several indications, because neurological toxicity is one of the defining early complications.
• Graft-versus-host disease or ongoing immunosuppression after an allogeneic transplant — the immunosuppression usually has to be off before collection.
• Disease moving faster than manufacturing — if bridging treatment cannot hold the disease for the weeks the dose takes to make, the centre may decline rather than start something you cannot finish.
• A failed collection — too few T cells harvested to make a dose. A second attempt is sometimes possible; a batch that fails release testing means starting again from collection.
• Pregnancy — excluded, and contraception is required around treatment.
• No caregiver, or no way to stay near the centre — the monitoring period after infusion is part of the treatment, not an optional extra, and centres treat it as an eligibility question.
• Funding not in place — the hardest exclusion in India, and the one families most often meet last instead of first.

Being turned down at one point in time is not always a permanent answer. Ask for the reason in writing, ask whether it is fixed or fixable, and ask what would have to change for the answer to be different.

1. 1

   The diagnosis is confirmed, in detail

   Pathology and immunophenotyping establish the exact subtype and whether the target antigen is present. An old summary letter is not enough; centres want the reports themselves.

2. 2

   The treatment history is reconstructed line by line

   Which regimens, in what order, with what response and what dates. Approvals are written around prior lines, so gaps in this history stall the assessment more often than anything clinical.

3. 3

   Referral to an accredited cell-therapy centre

   Only centres with intensive-care backup and toxicity medicines on standby may assess and infuse. A hospital without that accreditation cannot make the decision, whatever it offers.

4. 4

   The fitness workup

   Echocardiogram, oxygen assessment, kidney and liver bloods, infection screening, current imaging and, for some indications, a neurological or cerebrospinal-fluid assessment.

5. 5

   Funding and logistics are settled before collection

   Centres want the money and the accommodation arranged before apheresis, because a dose that cannot be paid for or a patient who cannot stay nearby leaves the treatment unfinished.

6. 6

   An apheresis slot and a bridging plan

   Collection is scheduled, and a bridging treatment is planned to hold the disease steady while the dose is manufactured. The bridging plan is part of the eligibility judgement, not an afterthought.

7. 7

   Eligibility is re-checked before infusion

   Being accepted in week one is not the same as being admitted in week six. If you deteriorate or develop an infection during manufacturing, the decision is revisited. Families should be told this in advance.

Ask the treating team to write down four things: the reason you were declined, whether it is fixed or fixable, what the next standard treatment would be, and what the goal of that treatment is. Written answers are harder to misremember at home and much easier to take for a second opinion.

Clinical trials are worth asking about, and worth understanding correctly. A trial is a study, not a promise of access or benefit, and no page can enrol you in one. Your haemato-oncologist and the accredited centres are the people who know which studies are open for your exact diagnosis and prior treatment.

Cost is a real eligibility factor in India, so treat it as one. On published reports, list prices for internationally approved CAR-T products have sat in the region of several crore rupees for the product alone, before hospital and monitoring costs; India’s domestically developed therapy was reported at a small fraction of that at launch. Both figures are indicative, as of August 2026, and come from published manufacturer and news reports rather than a CION rate card. CION does not provide CAR-T and quotes no price for it. Ask the accredited centre for a written estimate that separates the product, the hospital stay and the monitoring, and ask what scheme cover, if any, applies to you.

What CION can do sits earlier in the journey. We will review your reports, tell you plainly whether your diagnosis and treatment history put you anywhere near the eligibility criteria, explain what the pathway would involve, and give you a written second opinion on the treatment you have already been offered. Where a referral to an accredited cell-therapy centre is the right next step, we will say so. The immunotherapy given as day care at CION centres is checkpoint-inhibitor therapy, a different class with a different mechanism and a different side-effect pattern; response-assessment PET-CT during that treatment is coordinated at partner imaging centres rather than owned by CION.

• Cytokine Release Syndrome (CRS): The Main CAR-T Complication — the reaction that most of the fitness criteria on this page exist to protect you from, and why it dictates where CAR-T can be given.
• Indian-Made CAR-T vs Imported: Is There a Difference? — useful once you know you clear the clinical gates and the remaining question is access and cost.
• Honest Long-Term Outcomes After CAR-T — what is genuinely known and not known about the years after infusion, so eligibility is weighed against a realistic picture.
• Immunotherapy at CION Cancer Clinics — the treatments CION does provide, how eligibility for them is assessed, and what a first consultation covers.

This page is general information and does not replace a consultation. CION Cancer Clinics does not provide CAR-T or any cell therapy; immunotherapy at CION means checkpoint-inhibitor treatment given as day care, with response-assessment PET-CT coordinated at partner imaging centres. Eligibility criteria are set per therapy, per regulator and per centre, and change over time. Cost figures are indicative, as of August 2026, and drawn from published reports. Only an accredited cell-therapy centre, reviewing your complete case, can confirm whether you are eligible.

Most families ask about CAR-T long before it is on the table

If you have read about CAR-T and want to know whether the eligibility criteria have anything to do with your diagnosis, ask us. You will get a plain answer, including when the answer is no.